Olympia 1

Section NCT
Category Hematological neoplasms
Subcategory Non-Hodgkin lymphoma
Trial Type First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts AN OPEN-LABEL, RANDOMIZED, PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA
Description for laymen AN OPEN-LABEL, RANDOMIZED, PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA
JSON Data { "short_title": "Olympia 1", "data_mode": "910", "data_mode_number": "000000054", "official_title": null, "accrual_state": "running", "therapeutic_value": "not_applicable", "therapieansatz_value": "not_applicable", "therapieintervention_value": "not_applicable", "therapielinie_value": "first", "ctgov_number": null, "eudract_number": "2022-502660-20-00", "general_contact_email": "sal-aml-register@ukdd.de", "general_contact_phone": "+49 351-45818380", "hauptpruefer_dd_name": null, "description_laie_de": "EINE OFFENE, RANDOMISIERTE PHASE-III-STUDIE ZUM VERGLEICH DER WIRKSAMKEIT UND SICHERHEIT VON ODRONEXTAMAB (REGN1979), EINEM BISPEZIFISCHEN ANTI-CD20 X ANTI-CD3-ANTIK\u00d6RPER, GEGEN\u00dcBER DER WAHL DES PR\u00dcFARZTES BEI ZUVOR UNBEHANDELTEN TEILNEHMERN MIT FOLLIKUL\u00c4REM LYMPHOM", "description_laie_en": "AN OPEN-LABEL, RANDOMIZED, PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA", "description_expert_de": "EINE OFFENE, RANDOMISIERTE PHASE-III-STUDIE ZUM VERGLEICH DER WIRKSAMKEIT UND SICHERHEIT VON ODRONEXTAMAB (REGN1979), EINEM BISPEZIFISCHEN ANTI-CD20 X ANTI-CD3-ANTIK\u00d6RPER, GEGEN\u00dcBER DER WAHL DES PR\u00dcFARZTES BEI ZUVOR UNBEHANDELTEN TEILNEHMERN MIT FOLLIKUL\u00c4REM LYMPHOM", "description_expert_en": "AN OPEN-LABEL, RANDOMIZED, PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA", "rechtsgrundlage_value": null, "phase_amg_value": null, "main_cat_id": 4, "sub_cat_id": 24 }
Settings
Short name 910-000000054